The stock price for Neffy (which is a brand name for epinephrine nasal spray) is not directly traded as a separate entity. Instead, Neffy is manufactured and marketed by ARS Pharmaceuticals (NASDAQ: ARS). Therefore, to find information related to the financial performance or "stock price" associated with Neffy, one would need to look at the stock performance of ARS Pharmaceuticals.
What is Neffy used for?
Neffy is a medication approved for the treatment of anaphylaxis, a severe, potentially life-threatening allergic reaction. It is administered as a nasal spray [1].
How does Neffy work?
Neffy delivers epinephrine through the nasal passages. Epinephrine is a hormone that constricts blood vessels, increases heart rate, and opens airways, counteracting the effects of anaphylaxis [1].
When did Neffy become available?
Neffy was approved by the U.S. Food and Drug Administration (FDA) in July 2023 [2].
What is the ticker symbol for the company that makes Neffy?
The ticker symbol for ARS Pharmaceuticals, the company that developed Neffy, is ARS on the NASDAQ stock exchange [2].
Where can I find ARS Pharmaceuticals stock information?
Stock price data for ARS Pharmaceuticals (ARS) can be found on financial news websites and stock tracking platforms. Investors and interested parties can monitor the company's performance through its ticker symbol on exchanges like NASDAQ [2].
Are there other epinephrine nasal sprays?
Neffy is the first FDA-approved epinephrine nasal spray for anaphylaxis [2]. Currently, there are no other FDA-approved epinephrine nasal sprays for this indication.
What is the market potential for Neffy?
Anaphylaxis affects a significant number of people, and epinephrine is the first-line treatment. The availability of a nasal spray offers an alternative to injectable epinephrine auto-injectors, potentially addressing patient preferences and administration challenges. ARS Pharmaceuticals has highlighted the market need for improved anaphylaxis treatments [1][2].